CD47 and neoplasm: In particular, magrolimab (Hu5F9-G4, ONO-7913) is a humanized monoclonal antibody that binds CD47 at low nanomolar affinity and is built on an IgG4 scaffold to minimize Fc-mediated effector toxicity for non-tumor cells expressing CD47 [117].